Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Updates '09 Guidance; Expects 2 Percent Revenue Decline

NEW YORK (GenomeWeb News) – Bruker today provided updated financial guidance for fiscal year 2009, saying in a presentation at the Thomas Weisel Partners Healthcare Conference in Boston that it expects a year-over-year revenue decline of approximately 2 percent.

The firm had previously said that it expected flat to a low single-digit decline in revenues for the year.

Bruker also said that it is not likely to meet its previous goal of improving upon its 2008 earnings per share of $.45.

However, Bruker said that global stimulus programs could contribute 5 percent — roughly $50 million — or greater revenue growth its core scientific business instruments business in 2010.

Two weeks ago, the firm had revealed in a filing with the US Securities and Exchange Commission that it had taken in $10 million in orders due to stimulus programs in the US, Japan, and Europe.

In early trade on the Nasdaq, shares of Bruker were up 2 percent at $11.

Filed under

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.